AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.01, Bloomberg Earnings reports. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 273.65%. The business had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 11.76% on Wednesday, reaching $3.00. 1,579,487 shares of the company’s stock traded hands. The firm’s 50-day moving average is $2.65 and its 200 day moving average is $2.77. AcelRx Pharmaceuticals has a 12 month low of $1.95 and a 12 month high of $4.08. The firm’s market cap is $136.14 million.
WARNING: This piece of content was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/02/acelrx-pharmaceuticals-inc-nasdaqacrx-issues-quarterly-earnings-results-misses-expectations-by-0-01-eps.html.
ACRX has been the topic of several recent research reports. ValuEngine downgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, July 14th. Piper Jaffray Companies set a $3.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, July 25th. Finally, Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. AcelRx Pharmaceuticals presently has an average rating of “Hold” and an average target price of $7.86.
In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $2.40, for a total transaction of $2,100,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 28.10% of the stock is owned by corporate insiders.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
